Dashboard
Manage Tickers

CRBU


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-caribou-biosciences-raises-price-target-to-9
HC Wainwright & Co. Maintains Buy on Carib...
11/05/2025 11:40:40

HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and raises the price tar...

why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today
Why Is CRISPR Genome-Editing Firm Caribou ...
11/03/2025 16:48:45

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and mye...

citigroup-maintains-buy-on-caribou-biosciences-raises-price-target-to-8
Citigroup Maintains Buy on Caribou Bioscie...
11/03/2025 15:17:54

Citigroup analyst Yigal Nochomovitz maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and raises the price target from ...

caribou-biosciences-shared-its-first-clinical-data-from-dose-escalation-in-the-ongoing-cammouflage-phase-1-trial-of-cb-011-an-off-the-shelf-anti-bcma-car-t-cell-therapy-in-relapsed-or-refractory-multiple-myeloma-the-company-plans-to-share-dose-expansion-data-in-2026
Caribou Biosciences Shared Its First Clini...
11/03/2025 12:14:01

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapse...

caribou-biosciences-released-results-from-its-ongoing-antler-phase-1-trial-of-vispacabtagene-regedleucel-formerly-cb-010-an-allogeneic-anti-cd9-car-t-cell-therapy-for-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma
Caribou Biosciences Released Results From ...
11/03/2025 12:11:09

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous C...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
11/03/2025 12:05:47

why-lucas-gc-shares-are-trading-higher-by-over-36-here-are-20-stocks-moving-premarket
Why Lucas GC Shares Are Trading Higher By ...
11/03/2025 10:09:58

reported-sunday-caribou-biosciences-schedules-webcast-to-share-key-updates-from-antler-and-cammouflage-trials-and-outline-next-steps-for-allogeneic-car-t-pipeline
Reported Sunday, Caribou Biosciences Sched...
11/03/2025 07:53:23

correction-caribou-biosciences-q2-adj-eps-035-beats-039-estimate-sales-2667m-beat-2465m-estimate
CORRECTION: Caribou Biosciences Q2 Adj. EP...
08/12/2025 22:33:13

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $...

fda-halts-trials-exporting-americans-cells-to-hostile-countries-for-genetic-engineering
FDA Halts Trials Exporting Americans' Cell...
06/20/2025 17:59:07

FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exempt...

caribou-biosciences-q1-eps-043-beats-044-estimate-sales-235m-beat-175m-estimate
Caribou Biosciences Q1 EPS $(0.43) Beats $...
05/08/2025 20:50:09

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $...

hc-wainwright--co-maintains-buy-on-caribou-biosciences-lowers-price-target-to-3
HC Wainwright & Co. Maintains Buy on Carib...
04/28/2025 17:52:40

HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price tar...

caribou-biosciences-discontinues-gallop-phase-1-trial-of-cb-010-for-lupus-reduces-workforce-by-23-estimates-cash-payments-of-25m-35m-from-reduction-in-force-and-prioritization
Caribou Biosciences Discontinues GALLOP Ph...
04/24/2025 20:25:55

caribou-biosciences-prioritizes-oncology-pipeline-streamlines-operations-to-focus-on-cb-010-and-cb-011-clinical-programs-with-clinical-data-disclosures-now-planned-for-h2-2025
Caribou Biosciences Prioritizes Oncology P...
04/24/2025 20:25:05

-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one...

hc-wainwright--co-reiterates-buy-on-caribou-biosciences-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Cari...
03/19/2025 10:59:47

HC Wainwright & Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:CRBU) with a Buy and maintains $9 price ...

caribou-biosciences-expects-2494m-in-cash-and-equivalents-to-fund-current-operating-plan-into-h2-2026
Caribou Biosciences Expects $249.4M In Cas...
03/10/2025 20:30:28

caribou-biosciences-q4-2024-gaap-eps-039-beats-042-estimate-sales-208m-miss-211m-estimate
Caribou Biosciences Q4 2024 GAAP EPS $(0.3...
03/10/2025 20:12:54

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $...

reported-earlier-caribou-biosciences-advances-cb-010-cb-011-and-cb-012-programs-with-key-clinical-updates-expected-in-2025-cash-position-281m
Reported Earlier, Caribou Biosciences Adva...
01/13/2025 07:33:53

-- CB-010 GALLOP Phase 1 trial initiated in lupus ---- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no D...

b-of-a-securities-maintains-buy-on-caribou-biosciences-lowers-price-target-to-11
B of A Securities Maintains Buy on Caribou...
01/07/2025 17:49:33

B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target ...

caribou-biosciences-appoints-sri-ryali-as-cfo
Caribou Biosciences Appoints Sri Ryali As CFO
01/02/2025 13:08:51

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION